Not applicableApproved For MarketingNCT04204928
What this trial is testing
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid Cancer
Blueprint Medicines Corporation